drugset / Trial / NCT02761005

Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori

NCT02761005

Phase 2 Unknown 100 enrolled Hamamatsu University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Patients infected with H. pylori are treated with the individualized regimen which is based on the mutation of 23S rRNA of H. pylori.

Timeline

Start
2016-05
Primary completion
2018-03
Completion
2018-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule 200 mg
Subject Metronidazole Small molecule 250 mg
Background Amoxicillin Other / unclassified 750 mg
Background Vonoprazan Other / unclassified 20 mg